WEST Search History

DATE: Thursday, May 22, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L5	WO-9858667-$.did.	2	L5
L4	L3	0	L4
DB=PGPB; PLUR=YES; OP=ADJ			
L3	hyperactive t cell	0	L3
DB=USPT; PLUR=YES; OP=ADJ			
L2	hyperactive t cell	1	L2
L1	hyperactive t cells	1	L1

END OF SEARCH HISTORY

```
* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:32:00 ON 22 MAY 2003

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS,
       BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT,
       CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE,
       DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 16:32:07 ON 22 MAY 2003

67 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (hyperactive t-cell)
          1   FILE BIOSIS
          1   FILE BIOTECHABS
          1   FILE BIOTECHDS
          1   FILE BIOTECHNO
  12 FILES SEARCHED...
          2   FILE CANCERLIT
          3   FILE CAPLUS
  23 FILES SEARCHED...
          3   FILE EMBASE
  32 FILES SEARCHED...
  44 FILES SEARCHED...
          3   FILE MEDLINE
          1   FILE PHARMAML
          1   FILE PHIN
          1   FILE PROMT
          2   FILE SCISEARCH
  60 FILES SEARCHED...
          2   FILE TOXCENTER
          2   FILE WPIDS
  66 FILES SEARCHED...
          2   FILE WPINDEX

  15 FILES HAVE ONE OR MORE ANSWERS,   67 FILES SEARCHED IN STNINDEX

L1   QUE (HYPERACTIVE T-CELL)

=> d rank
F1            3   CAPLUS
F2            3   EMBASE
F3            3   MEDLINE
F4            2   CANCERLIT
F5            2   SCISEARCH
F6            2   TOXCENTER
F7            2   WPIDS
F8            2   WPINDEX
F9            1   BIOSIS
F10           1   BIOTECHABS
F11           1   BIOTECHDS
F12           1   BIOTECHNO
F13           1   PHARMAML
F14           1   PHIN
F15           1   PROMT
```

```
=> file f1-15
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.20       2.41

FILE 'CAPLUS' ENTERED AT 16:34:23 ON 22 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:34:23 ON 22 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'MEDLINE' ENTERED AT 16:34:23 ON 22 MAY 2003

FILE 'CANCERLIT' ENTERED AT 16:34:23 ON 22 MAY 2003

FILE 'SCISEARCH' ENTERED AT 16:34:23 ON 22 MAY 2003
COPYRIGHT 2003 THOMSON ISI

FILE 'TOXCENTER' ENTERED AT 16:34:23 ON 22 MAY 2003
COPYRIGHT (C) 2003 ACS

FILE 'WPIDS' ENTERED AT 16:34:23 ON 22 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'BIOSIS' ENTERED AT 16:34:23 ON 22 MAY 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 16:34:23 ON 22 MAY 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 16:34:23 ON 22 MAY 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'PHARMAML' ENTERED AT 16:34:23 ON 22 MAY 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIN' ENTERED AT 16:34:23 ON 22 MAY 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 16:34:23 ON 22 MAY 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

=> s l1
   4 FILES SEARCHED...
   8 FILES SEARCHED...
L2          23 L1

=> dup rem l2
DUPLICATE IS NOT AVAILABLE IN 'PHARMAML'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L2
L3            11 DUP REM L2 (12 DUPLICATES REMOVED)
                 ANSWERS '1-3' FROM FILE CAPLUS
                 ANSWERS '4-5' FROM FILE EMBASE
                 ANSWER '6' FROM FILE TOXCENTER
                 ANSWERS '7-8' FROM FILE WPIDS
                 ANSWER '9' FROM FILE PHARMAML
                 ANSWER '10' FROM FILE PHIN
                 ANSWER '11' FROM FILE PROMT
```

=> d bib abs 1-11

L3 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 2
AN 1999:27731 CAPLUS
DN 130:76171
TI Use of proteolytic enzymes for treating glomerulonephritis
IN Stauder, Gerhard; Ransberger, Karl
PA Mucos Pharma G.m.b.H. & Co., Germany
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9858667	A1	19981230	WO 1998-EP3769	19980619
	W: US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19726253	A1	19981224	DE 1997-19726253	19970620
	DE 19726253	C2	20000316		
	EP 920332	A1	19990609	EP 1998-934986	19980619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	DE 1997-19726253		19970620		
	WO 1998-EP3769		19980619		

AB Proteinases, particularly trypsin, bromelain, and papain, are administered for enzymic dissoln. of immune complexes deposited in the glomeruli in treatment of glomerulonephritis. The therapeutic effect of proteinases may also involve actions on cytokines, leukocyte cytokine receptors such as CD2, CD4, CD11b, and CD25, endogenous metalloproteinases, cell adhesion mols., and **hyperactive T-cells**.
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 4
AN 1987:494856 CAPLUS
DN 107:94856
TI In vitro studies on leukemic cells and T lymphocytes in hairy cell leukemia
AU Ford, Richard J.; Mehta, Shashi; Sharma, Surendra
CS M. D. Anderson Hosp. Tumor Inst., Univ. Texas, Houston, TX, 77030, USA
SO Leukemia (1987), 1(4), 386-9
CODEN: LEUKED; ISSN: 0887-6924
DT Journal
LA English
AB Hairy cell leukemia cell lines were established from 8 untreated patients using purified B cell growth factor (BCGF) in vitro. These cell lines maintained their original cell surface immunophenotype for about 1 mo, after which they began to lose 1 or more of their characteristic surface antigens. The cell lines also maintained typical hairy cell leukemia morphol. for 2-3 mo in vitro but later showed an increasing no. of multinucleate giant cells that maintained a B cell surface phenotype. The cell lines became independent of exogenously provided BCGF after at least 1 mo in vitro and secreted BCGF activity into culture supernatants in most cases. Some cell lines also acquired Epstein-Barr virus nuclear antigen positivity after variable period. Two hairy cell leukemia patients also showed **hyperactive T cell** responses in vitro
and exhibited spontaneous T cell proliferation in culture without exogenously supplied interleukin-2. These T cell lines had the T helper phenotype and secreted significant amts. of T cell-assocd. lymphokines with BCGF and interleukin-2 activity into culture supernatants.

L3 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2003 ACS

AN 2000:260036 CAPLUS
DN 132:274331
TI Use of proteolytic enzymes to influence **hyperactive T-cells**
IN Ransberger, Karl; Stauder, Gerhard
PA Mucos Pharma G.m.b.H. & Co., Germany
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000021547	A2	20000420	WO 1999-EP7634	19991012
WO 2000021547	A3	20000908		
W: CA, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
DE 19847114	A1	20000420	DE 1998-19847114	19981013
EP 1121146	A2	20010808	EP 1999-953778	19991012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI DE 1998-19847114	A	19981013		
WO 1999-EP7634	W	19991012		

priority doc

AB The use of at least one proteolytic enzyme to influence **hyperactive T cells** is disclosed. Preferred proteolytic enzymes are trypsin, bromelain and papain. Rutin can addnl. be used.

L3 ANSWER 4 OF 11 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 3
AN 1998361153 EMBASE
TI Immunopathogenesis of SLE.
AU Mason L.J.; Isenberg D.A.
CS L.J. Mason, Bloomsbury Rheumatology Unit, Department of Medicine, University College London, 40-50 Tottenham Street, London W1P 9PG, United Kingdom
SO Bailliere's Clinical Rheumatology, (1998) 12/3 (385-403).
Refs: 51
ISSN: 0950-3579 CODEN: BCRHEZ
CY United Kingdom
DT Journal; Article
FS 026 Immunology, Serology and Transplantation
031 Arthritis and Rheumatism
037 Drug Literature Index
LA English
SL English
AB Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by the deposition of autoantibodies and immune complexes, leading to tissue damage. The immunopathogenesis of SLE is like a jigsaw puzzle, some pieces of which are missing or have not fallen into place. In predisposed individuals, the initial stimulus is likely to be one or more of the environmental agents interacting with susceptibility genes. Once the critical threshold is breached there is a failure of the immune system to downregulate the ensuing abnormal immune response, involving polyclonal B cell activation and **hyperactive T cell** help. Key questions include, what are the processes behind the availability of autoantigens and the breakdown of tolerance that give rise to the pathogenic autoantibodies? Current areas of research also involve the roles played by cytokines, adhesion molecules, co-stimulatory molecules and apoptosis.

L3 ANSWER 5 OF 11 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 6
AN 77039476 EMBASE
DN 1977039476
TI **Hyperactive T cell** function in young NZB

mice; Increased proliferative responses to allogenic cells.
AU Palmer D.W.; Dauphinee M.J.; Murphy E.; Talal N.
CS Dept. Med., Univ. California, San Francisco, Calif., United States
SO Clinical and Experimental Immunology, (1976) 23/3 (578-581).
CODEN: CEXIAL
DT Journal
FS 026 Immunology, Serology and Transplantation
005 General Pathology and Pathological Anatomy
LA English
AB The one way mixed lymphocyte reaction was employed to study proliferative responses to antigens by mature, immunocompetent T cells from NZB mice 3 wk to 4 mth old. Compared to cells from control mice of the same H-2 type, thymus, spleen and lymph node cells from NZB mice were hyperactive in this response. The results are discussed in relation to possible effects of chronic stimulation by endogenous type C leukaemia virus upon differentiation of functional T cells or upon regulation by T cells of other T cell functions, including augmentation of antibody responses.

L3 ANSWER 6 OF 11 TOXCENTER COPYRIGHT 2003 ACS DUPLICATE 5
AN 1981:44408 TOXCENTER
CP Copyright 2003 BIOSIS
DN BR20:48201
TI KINETIC ANALYSES OF NZB CYTO TOXIC LYMPHOCYTES
AU HUSTON D P; CARMONA M A; STEINBERG A D
CS BETHESDA, MD., USA.
SO 44TH ANNUAL MEETING OF THE AMERICAN RHEUMATISM ASSOCIATION, ATLANTA, GA., USA, MAY 27-30, 1980. ARTHRITIS RHEUM. Arthritis Rheum., (1980) 23 (6), 692.
CODEN: ARHEAW. ISSN: 0004-3591.
DT Conference
FS BIOSIS
OS BIOSIS 1981:48201
LA English
ED Entered STN: 20011116
Last Updated on STN: 20011116

L3 ANSWER 7 OF 11 WPIDS (C) 2003 THOMSON DERWENT DUPLICATE 1
AN 2000-304694 [27] WPIDS
DNC C2000-092673
TI Use of proteolytic enzymes to modulate **hyperactive T cells**, especially for symptomatic treatment of immune-mediated inflammatory diseases, e.g. multiple sclerosis, diabetes, arthritis or glomerulonephritis.
DC B04 D16
IN RANSBERGER, K; STAUDER, G
PA (MUCO-N) MUCOS PHARMA GMBH & CO
CYC 21
PI DE 19847114 A1 20000420 (200027)* 15p
WO 2000021547 A2 20000420 (200027) DE
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: CA US
EP 1121146 A2 20010808 (200146) DE
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
ADT DE 19847114 A1 DE 1998-19847114 19981013; WO 2000021547 A2 WO 1999-EP7634 19991012; EP 1121146 A2 EP 1999-953778 19991012, WO 1999-EP7634 19991012
FDT EP 1121146 A2 Based on WO 200021547
PRAI DE 1998-19847114 19981013
AN 2000-304694 [27] WPIDS
AB DE 19847114 A UPAB: 20000606
NOVELTY - One or more proteolytic enzymes are used, optionally together with rutoside, to modulate **hyperactive T cells**

USE - For symptomatic treatment of immune-mediated inflammatory diseases, e.g. multiple sclerosis, type I diabetes, rheumatoid arthritis or glomerulonephritis.

Dwg.0/6

L3 ANSWER 8 OF 11 WPIDS (C) 2003 THOMSON DERWENT
AN 1999-061611 [06] WPIDS
DNC C1999-018514
TI Treatment of glomerulonephritis without side effects - using proteolytic enzyme(s), especially trypsin, bromelain and/or papain, optionally in combination with rutoside.
DC B04 D16
IN RANSBERGER, K; STAUDER, G
PA (MUCO-N) MUCOS PHARMA GMBH & CO
CYC 20
PI DE 19726253 A1 19981224 (199906)* 14p
WO 9858667 A1 19981230 (199907) DE
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
W: US
EP 920332 A1 19990609 (199927) DE
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DE 19726253 C2 20000316 (200018)
ADT DE 19726253 A1 DE 1997-19726253 19970620; WO 9858667 A1 WO 1998-EP3769 19980619; EP 920332 A1 EP 1998-934986 19980619, WO 1998-EP3769 19980619; DE 19726253 C2 DE 1997-19726253 19970620
FDT EP 920332 A1 Based on WO 9858667
PRAI DE 1997-19726253 19970620
AN 1999-061611 [06] WPIDS
AB DE 19726253 A UPAB: 19990210
Use of at least one proteolytic enzyme and optionally rutoside, for treating glomerulonephritis, is new.
USE - The proteolytic enzymes may act by breaking up deposits of immune complexes in tissue affected by glomerulonephritis. They may also act by effecting altered cellular expression of cytokines, cytokine receptors, endogenous tissue metalloproteases or cellular adhesion molecules. Alternatively they may act by effecting reductions in the amount of **hyperactive T-cells**.
ADVANTAGE - No damaging side effects are observed, even with use of the enzymes (or combination of enzymes) over a long period of time.
Dwg.0/5

L3 ANSWER 9 OF 11 PHARMAML COPYRIGHT 2003 MARKETLETTER
AN 1635213 PHARMAML
TI Xoma Receives $8m From Genentech For Psoriasis Drug
SO Marketletter December 16, 1996
DT Newsletter
WC 71
TX - Xoma has received an $8.5 million milestone payment from Genentech to cover the expense of developing its psoriasis drug, hu1124 (antiCD11a monoclonal antibody), through 1997. The company has started a Phase I trial of the product in 30-40 patients with moderate to severe psoriasis. The product is designed to block the **hyperactive T cell** reaction which occurs in psoriasis patients. It is also in development to treat organ transplant rejection.

L3 ANSWER 10 OF 11 PHIN COPYRIGHT 2003 PJB

AN 1998:19358 PHIN
DN B00600446
DED 1 Oct 1998
TI Rigel Inc.: A Laboratory in a Cell
SO Bioventure-View (1998) No. 1310 p1
DT Newsletter
FS FULL

L3 ANSWER 11 OF 11 PROMT COPYRIGHT 2003 Gale Group

AN 96:647818 PROMT

TI Xoma Receives $8m From Genentech For Psoriasis Drug
SO Marketletter, (16 Dec 1996) pp. N/A.
ISSN: 0951-3175.
LA English
WC 71
FULL TEXT IS AVAILABLE IN THE ALL FORMAT
AB - Xoma has received an $8.5 million milestone payment from Genentech to cover the expense of developing its psoriasis drug, hu1124 (antiCD11a monoclonal antibody), through 1997. The company has started a Phase I trial of the product in 30-40 patients with moderate to severe psoriasis. The product is designed to block the **hyperactive T cell** reaction which occurs in psoriasis patients. It is also in development to treat organ transplant rejection.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.24	50.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.95

STN INTERNATIONAL LOGOFF AT 16:38:47 ON 22 MAY 2003